|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash and due from banks | ||||||||||||||||||||
| Federal funds sold and overnight deposits | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Interest bearing deposits in banks | ||||||||||||||||||||
| Investment securities available-for-sale | ||||||||||||||||||||
| Other investments | ||||||||||||||||||||
| Total investments | ||||||||||||||||||||
| Loans held for sale | ||||||||||||||||||||
| Loans | ||||||||||||||||||||
| Allowance for credit losses on loans | ||||||||||||||||||||
| Net deferred loan costs | ||||||||||||||||||||
| Net loans | ||||||||||||||||||||
| Premises and equipment, net | ||||||||||||||||||||
| Company-owned life insurance | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Stockholders’ Equity | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Deposits | ||||||||||||||||||||
| Noninterest bearing | ||||||||||||||||||||
| Interest bearing | ||||||||||||||||||||
| Time | ||||||||||||||||||||
| Total deposits | ||||||||||||||||||||
| Borrowed funds | ||||||||||||||||||||
| Subordinated notes | ||||||||||||||||||||
| Accrued interest and other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders’ Equity | ||||||||||||||||||||
| Common stock, $2.00 par value; 7,500,000 shares authorized; 5,415,605 shares issued at June 30, 2026 and 5,084,635 shares issued at December 31, 2025 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Treasury stock at cost; 469,740 shares at June 30, 2026 and 471,430 shares at December 31, 2025 | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| Total liabilities and stockholders' equity | ||||||||||||||||||||
Loading...
